UGT2B17 and prostate neoplasm: Therefore, we scored the total UGT2B17 signal using Aperio ImageScope and found that UGT2B17 expression was 1.5- to 2.8-fold higher in primary prostate tumors compared with benign prostate tissue and 1.4- to 3-fold higher in CRPC than in primary tumors (Figure 1, A and B).